{"classes":[{"categories":[{"measurements":[{"comment":"Both palbociclib 75 mg+bortezomib+dexamethasone and palbociclib 100 mg+bortezomib+dexamethasone had DLT \\>1/6, hence no RP2D was selected from these 2 dosing groups.","groupId":"OG000","value":"NA"},{"groupId":"OG001","value":"100"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"12"}],"units":"Participants"}],"description":"RP2D was determined based on the MTD, safety and tolerability profile of the study treatment.","groups":[{"description":"Included all participants who received palbociclib (PD 0332991) 75 mg or 100 mg capsule orally once daily for 21 days followed by 7 days off-treatment in a 28-day cycle along with bortezomib 1.0 mg/m\\^2 intravenous injection and dexamethasone 20 mg tablet orally 30 minutes prior to bortezomib injection on Day 8, 11, 15 and 18 of 28-day cycle (schedule A) during Phase 1 of the study. Treatment was continued until any of the following withdrawal criteria was met: disease progression (unless the investigator judged that participant could still derive clinical benefit from continuing the treatment and the risk/benefit was still favorable), unacceptable toxicities, need for surgery or radiation therapy considered due to progressive disease by investigator, investigator conclusion that it is in the participant's best interest to discontinue therapy, need for anti-cancer therapy, lost to follow-up, withdrawal from treatment, or withdrawal of consent.","id":"OG000","title":"Palbociclib + Bortezomib + Dexamethasone (Phase1:Schedule A)"},{"description":"Included all participants who received palbociclib (PD 0332991) 100 mg or 125 mg capsule orally once daily for 12 days followed by 9 days off-treatment in a 21-day cycle along with bortezomib 1.0 mg/m\\^2 intravenous injection and dexamethasone 20 mg tablet orally 30 minutes prior to bortezomib injection on Day 8, 11, 15 and 18 of 21-day cycle (schedule B) during Phase 1 of the study. Treatment was continued until any of the following withdrawal criteria was met: disease progression (unless the investigator judged that participant could still derive clinical benefit from continuing the treatment and the risk/benefit was still favorable), unacceptable toxicities, need for surgery or radiation therapy considered due to progressive disease by investigator, investigator conclusion that it is in the participant's best interest to discontinue therapy, need for anti-cancer therapy, lost to follow-up, withdrawal from treatment, or withdrawal of consent.","id":"OG001","title":"Palbociclib + Bortezomib + Dexamethasone (Phase1:ScheduleB)"}],"paramType":"NUMBER","populationDescription":"DLT analysis set included all enrolled participants who received at least one dose of study treatment and did not have a major deviation in the first cycle.","reportingStatus":"POSTED","timeFrame":"Day 1 up to Day 28 during Cycle 1 in schedule A, Day 1 up to Day 21 during Cycle 1 in schedule B","title":"Recommended Phase II Dose (RP2D) of PD-0332991: Phase 1","type":"PRIMARY","unitOfMeasure":"milligram (mg)"}